$AXGN SEC Filings

Filed On	Filing
02 Oct 2026	SCHEDULE 13G
01 Oct 2026	8-K: Regulation FD Disclosure Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
10 Sep 2026	424B5
10 Sep 2026	8-K/A: Entry into a Material Definitive Agreement; Regulation FD Disclosure This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of September 9, 2026, is entered into by and among Axogen, Inc., a Minnesota corporation (“Buyer”), Omega Merger Sub, Inc., a Georgia corporation and a wholly-owned subsidiar...
10 Sep 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more Axogen, Inc., a Minnesota corporation (the “Company”) confirms its agreement with BofA Securities, Inc. (“BofA Securities”), Jefferies LLC (“Jefferies”), Wells Fargo Securities, LLC (“Wells Fargo”) and each of the other Underwriters name...
04 Sep 2026	Form 4: Tyndall Joseph A., Director Sold 3,500 shares ($174K)
02 Sep 2026	144
14 Aug 2026	SCHEDULE 13G/A
12 Aug 2026	Form 4: Began Marc A, EVP & General Counsel Received 67,500 shares by exercise or conversion ($551K) · Sold 67,500 shares ($3.2M)
12 Aug 2026	Form 4: Wendell Amy McBride, Director Received 13,353 shares by exercise or conversion ($198K) · Sold 13,353 shares ($647K)
11 Aug 2026	144
11 Aug 2026	Form 4: Weiler Kathy Johnson, Director Sold 14,150 shares ($641K)
10 Aug 2026	144
07 Aug 2026	144
31 Jul 2026	SCHEDULE 13G/A
29 Jul 2026	FORM 10-Q
29 Jul 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
26 Jun 2026	Form 4: Burke William P. Mr., Director Granted 4,392 Restricted Stock Units
26 Jun 2026	Form 4: Johnson John, Director Granted 4,392 Restricted Stock Units
26 Jun 2026	Form 4: Levine Alan M, Director Granted 4,392 Restricted Stock Units

Comments